Assetmark Inc. grew its position in Amgen, Inc. (NASDAQ:AMGN) by 19.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,867 shares of the medical research company’s stock after buying an additional 1,625 shares during the period. Assetmark Inc.’s holdings in Amgen were worth $1,818,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Advisors Preferred LLC acquired a new stake in shares of Amgen in the 2nd quarter valued at $30,000. Arbor Wealth Management LLC grew its position in shares of Amgen by 154.5% in the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after buying an additional 102 shares during the last quarter. C J Advisory Inc purchased a new position in shares of Amgen in the 1st quarter valued at $40,000. Ashburton Jersey Ltd purchased a new position in shares of Amgen in the 2nd quarter valued at $42,000. Finally, Sound Income Strategies LLC grew its position in shares of Amgen by 402.1% in the 2nd quarter. Sound Income Strategies LLC now owns 236 shares of the medical research company’s stock valued at $43,000 after buying an additional 189 shares during the last quarter. 76.24% of the stock is owned by institutional investors and hedge funds.
In related news, Director R Sanders Williams sold 425 shares of the firm’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $183.04, for a total value of $77,792.00. Following the completion of the transaction, the director now directly owns 16,336 shares of the company’s stock, valued at $2,990,141.44. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Ronald D. Sugar sold 2,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was sold at an average price of $206.70, for a total value of $413,400.00. Following the transaction, the director now owns 16,336 shares of the company’s stock, valued at $3,376,651.20. The disclosure for this sale can be found here. Insiders sold a total of 17,851 shares of company stock valued at $3,659,900 in the last quarter. 0.25% of the stock is currently owned by insiders.
AMGN opened at $194.94 on Friday. The stock has a market capitalization of $117.58 billion, a PE ratio of 13.54, a P/E/G ratio of 2.55 and a beta of 1.11. Amgen, Inc. has a 12-month low of $166.30 and a 12-month high of $211.90. The firm’s fifty day moving average price is $200.83 and its 200 day moving average price is $185.78. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.60.
Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The company had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The firm’s revenue was down 3.1% compared to the same quarter last year. During the same period in the prior year, the company earned $3.83 earnings per share. On average, equities research analysts forecast that Amgen, Inc. will post 14.3 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which was paid on Friday, September 6th. Investors of record on Thursday, August 15th were given a $1.45 dividend. The ex-dividend date was Wednesday, August 14th. This represents a $5.80 dividend on an annualized basis and a yield of 2.98%. Amgen’s dividend payout ratio is presently 40.28%.
Several research analysts have issued reports on the stock. BidaskClub downgraded shares of Amgen from a “hold” rating to a “sell” rating in a report on Thursday, September 12th. Cowen set a $231.00 price objective on shares of Amgen and gave the company a “buy” rating in a research note on Thursday, August 22nd. Wells Fargo & Co reiterated a “market perform” rating and issued a $220.00 price objective (up previously from $202.00) on shares of Amgen in a research note on Tuesday, August 27th. They noted that the move was a valuation call. Citigroup restated a “buy” rating on shares of Amgen in a research report on Monday, August 12th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $230.00 target price (up previously from $221.00) on shares of Amgen in a research report on Thursday, September 5th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and ten have issued a buy rating to the company’s stock. Amgen presently has a consensus rating of “Hold” and an average target price of $217.33.
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.
Featured Story: What is a good dividend yield?
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.